Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study

A. Riccio (Genoa, Italy), P. Mauri (Segrate, Italy), M. Bartezaghi (Origgio, Italy), F. Saccheri (Origgio, Italy), G. Canonica (Milan, Italy)

Source: International Congress 2018 – Innovative therapies in asthma and COPD
Session: Innovative therapies in asthma and COPD
Session type: Poster Discussion
Number: 604
Disease area: Airway diseases

Congress or journal article abstractSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Riccio (Genoa, Italy), P. Mauri (Segrate, Italy), M. Bartezaghi (Origgio, Italy), F. Saccheri (Origgio, Italy), G. Canonica (Milan, Italy). Serum GAL3 predict response in omalizumab-treated patients with severe allergic asthma: the PROXIMA study. 604

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: